RU2020100072A - Иммуногенные композиции, содержащие cea, muc1 и tert - Google Patents
Иммуногенные композиции, содержащие cea, muc1 и tert Download PDFInfo
- Publication number
- RU2020100072A RU2020100072A RU2020100072A RU2020100072A RU2020100072A RU 2020100072 A RU2020100072 A RU 2020100072A RU 2020100072 A RU2020100072 A RU 2020100072A RU 2020100072 A RU2020100072 A RU 2020100072A RU 2020100072 A RU2020100072 A RU 2020100072A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- nucleotide sequence
- amino acid
- acid sequence
- amino acids
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 29
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title claims 5
- 102100034256 Mucin-1 Human genes 0.000 title claims 5
- 239000000203 mixture Substances 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims 50
- 125000003729 nucleotide group Chemical group 0.000 claims 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 150000001413 amino acids Chemical class 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 230000000890 antigenic effect Effects 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 229940043367 IDO1 inhibitor Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531227P | 2017-07-11 | 2017-07-11 | |
| US62/531,227 | 2017-07-11 | ||
| US201862682044P | 2018-06-07 | 2018-06-07 | |
| US62/682,044 | 2018-06-07 | ||
| PCT/IB2018/054926 WO2019012371A1 (en) | 2017-07-11 | 2018-07-03 | IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020100072A true RU2020100072A (ru) | 2021-08-11 |
| RU2020100072A3 RU2020100072A3 (https=) | 2021-08-11 |
Family
ID=63720720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020100072A RU2020100072A (ru) | 2017-07-11 | 2018-07-03 | Иммуногенные композиции, содержащие cea, muc1 и tert |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190016775A1 (https=) |
| EP (1) | EP3651792A1 (https=) |
| JP (2) | JP7028953B2 (https=) |
| KR (1) | KR20200027551A (https=) |
| CN (1) | CN111065408A (https=) |
| AU (1) | AU2018300295A1 (https=) |
| BR (1) | BR112020000413A2 (https=) |
| CA (1) | CA3069363A1 (https=) |
| CO (1) | CO2020000231A2 (https=) |
| IL (1) | IL271917A (https=) |
| PE (1) | PE20200613A1 (https=) |
| PH (1) | PH12020500087A1 (https=) |
| RU (1) | RU2020100072A (https=) |
| SG (1) | SG11202000197PA (https=) |
| TW (1) | TW201920674A (https=) |
| WO (1) | WO2019012371A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020201219A1 (de) | 2020-01-31 | 2021-08-05 | United Initiators Gmbh | Transport- und Lagerbehälter für Peroxide |
| CA3183774A1 (en) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Breast cancer vaccine |
| CN112552380B (zh) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1341423C (en) | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6962790B1 (en) | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| TWI228718B (en) | 2001-11-05 | 2005-03-01 | Tdk Corp | Manufacturing method and device of mold plate for information medium |
| DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| CA2664168A1 (en) * | 2006-10-12 | 2008-04-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| US9128725B2 (en) | 2012-05-04 | 2015-09-08 | Apple Inc. | Load-store dependency predictor content management |
| DK3199552T3 (da) * | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| JP2014161283A (ja) * | 2013-02-26 | 2014-09-08 | Shizuoka Prefecture | Ｃｅａｃａｍ５遺伝子のスプライシングバリアント |
| MY174677A (en) * | 2013-08-21 | 2020-05-06 | Curevac Ag | Composition and vaccine for treating lung cancer |
| CN105682670A (zh) | 2013-10-28 | 2016-06-15 | 皮拉马尔企业有限公司 | 中药组合物及其制备方法和应用 |
| WO2015063647A1 (en) | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| EA201650031A1 (ru) | 2014-05-15 | 2017-06-30 | Итеос Терапьютик | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN107406857B (zh) * | 2015-01-09 | 2021-06-29 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
-
2018
- 2018-07-03 KR KR1020207003864A patent/KR20200027551A/ko not_active Ceased
- 2018-07-03 AU AU2018300295A patent/AU2018300295A1/en not_active Abandoned
- 2018-07-03 RU RU2020100072A patent/RU2020100072A/ru unknown
- 2018-07-03 EP EP18780215.2A patent/EP3651792A1/en not_active Withdrawn
- 2018-07-03 CA CA3069363A patent/CA3069363A1/en not_active Abandoned
- 2018-07-03 BR BR112020000413-8A patent/BR112020000413A2/pt not_active Application Discontinuation
- 2018-07-03 PE PE2020000050A patent/PE20200613A1/es unknown
- 2018-07-03 WO PCT/IB2018/054926 patent/WO2019012371A1/en not_active Ceased
- 2018-07-03 JP JP2020500687A patent/JP7028953B2/ja not_active Expired - Fee Related
- 2018-07-03 SG SG11202000197PA patent/SG11202000197PA/en unknown
- 2018-07-03 CN CN201880057887.4A patent/CN111065408A/zh active Pending
- 2018-07-06 TW TW107123509A patent/TW201920674A/zh unknown
- 2018-07-09 US US16/029,878 patent/US20190016775A1/en not_active Abandoned
-
2020
- 2020-01-08 IL IL271917A patent/IL271917A/en unknown
- 2020-01-10 PH PH12020500087A patent/PH12020500087A1/en unknown
- 2020-01-10 CO CONC2020/0000231A patent/CO2020000231A2/es unknown
-
2021
- 2021-10-27 JP JP2021175480A patent/JP2022031653A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201920674A (zh) | 2019-06-01 |
| JP7028953B2 (ja) | 2022-03-02 |
| CA3069363A1 (en) | 2019-01-17 |
| WO2019012371A1 (en) | 2019-01-17 |
| JP2020526202A (ja) | 2020-08-31 |
| PE20200613A1 (es) | 2020-03-11 |
| CO2020000231A2 (es) | 2020-01-17 |
| BR112020000413A2 (pt) | 2020-07-21 |
| KR20200027551A (ko) | 2020-03-12 |
| US20190016775A1 (en) | 2019-01-17 |
| JP2022031653A (ja) | 2022-02-22 |
| PH12020500087A1 (en) | 2020-09-14 |
| SG11202000197PA (en) | 2020-02-27 |
| IL271917A (en) | 2020-02-27 |
| EP3651792A1 (en) | 2020-05-20 |
| RU2020100072A3 (https=) | 2021-08-11 |
| CN111065408A (zh) | 2020-04-24 |
| AU2018300295A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021261945B2 (en) | Compositions and methods for generating an immune response to a tumor associated antigen | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2019510488A (ja) | 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター | |
| JP2017522312A5 (https=) | ||
| US20220160853A1 (en) | Cancer vaccine compositions and methods for use thereof | |
| Neukirch et al. | Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice | |
| JP2019517790A5 (https=) | ||
| RU2020100072A (ru) | Иммуногенные композиции, содержащие cea, muc1 и tert | |
| CA3206004A1 (en) | Viral constructs for use in enhancing t-cell priming during vaccination | |
| JP2024537250A (ja) | インフルエンザワクチン | |
| EP4357356A3 (en) | Antigenic peptides for prevention and treatment of b-cell malignancy | |
| JP2020526202A5 (https=) | ||
| RU2018126487A (ru) | Противораковые вакцины | |
| EP3762023A1 (en) | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins | |
| JP2019505210A5 (https=) | ||
| JP2017516462A5 (https=) | ||
| JP7635208B2 (ja) | Ｂ型肝炎ウイルスワクチン | |
| CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
| CN102898508B (zh) | 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途 | |
| EP3209784A1 (en) | Dna motif compounds and methods for inducing specific antibodies and cellular immunity | |
| RU2013135148A (ru) | Полиэпитопные иммуногенные полипептиды и способы их применения | |
| RU2021110614A (ru) | Противораковая вакцина с инвариантной цепью из костистых рыб | |
| NZ763337A (en) | Vaccine t cell enhancer | |
| HK40093155A (zh) | 用於产生对肿瘤相关抗原的免疫应答的组合物和方法 | |
| CN118922204A (zh) | 流感疫苗 |